Related Experiment Video

Updated: Jul 8, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

New treatment approaches for prostate cancer based on peptide analogues

Anton Stangelberger1, Andrew V Schally, Bob Djavan

  • 1Department of Urology University of Vienna, Vienna, Austria.

European Urology
|January 19, 2008
PubMed
Abstract

Insights

New peptide analogue therapies, including luteinising hormone-releasing hormone (LHRH) and somatostatin analogues, show promise for advanced prostate cancer. These targeted treatments offer new avenues for hormone therapy and chemotherapy.

Area of Science:

  • Oncology
  • Endocrinology
  • Peptide Therapeutics

Background:

  • Advanced prostate cancer treatment remains a challenge.
  • Neuropeptides and their receptors play a role in prostate cancer proliferation and progression.

Purpose of the Study:

  • To review novel therapeutic strategies for advanced prostate cancer utilizing peptide analogues.
  • To explore the potential of targeting specific peptide receptors on cancer cells.

Main Methods:

  • Review of current literature on peptide analogue therapies.
  • Analysis of the role of luteinising hormone-releasing hormone (LHRH), somatostatin, growth hormone-releasing hormone (GHRH), and bombesin/gastrin-releasing peptide (BN/GRP) pathways.

Main Results:

  • LHRH analogues induce androgen deprivation, with potential direct anti-tumour effects.
  • Radiolabeled somatostatin analogues aid in tumour localization.
  • GHRH and BN/GRP antagonists, along with cytotoxic peptide analogues, are emerging as promising therapeutic agents.

Conclusions:

  • Targeted therapies using peptide analogues represent a significant advancement in treating advanced prostate cancer.
  • These novel approaches may enhance hormone therapy and enable targeted chemotherapy for improved patient outcomes.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...